Clinical trials commitment earns industry award
4 Nov 2019
The Director of USC Clinical Trials, Lucas Litewka, has been recognised nationally for his significant contribution to the medical technology and pharmaceuticals (MTP) sector.
Mr Litewka was named Sector Advocate at a recent awards ceremony held in Sydney as part of the Association of Regulatory and Clinical Scientists (ARCS) annual conference.
ARCS is a professional association for people working in the development of therapeutic goods.
Mr Litewka, who is a Director and Board Member of the association, said he was surprised to receive the award and proud to represent the MTP sector.
“It is such a dynamic industry to be involved in and I’m driven to constantly improve and support the sector to do the same,” he said.
“Patients are desperate to find solutions, and as an industry, we are always striving to speed up the development of new treatments that will help them overcome their illnesses or medical conditions.”
Mr Litewka was appointed as the inaugural Director of USC Clinical Trials in 2015 following work as a senior medical scientist and the Clinical Trials Business Development Manager at St Vincent’s Hospital in Melbourne.
“I’ve had some wonderful professional opportunities, but I have to say that my time at USC is a career highlight for me,” he said.
“This role has expanded my mind to what is possible, and the support of USC has given my team and me the freedom to explore new possibilities.
“Being able to try new things and push the boundaries means we have every possible chance to make our initiative stand out not only locally but also internationally, which makes USC Clinical Trials an exciting place to be.”
USC to welcome 5,500 new students during O Week22 Feb
Hundreds of new USC students from across Australia brought colour and excitement to the Sunshine Coast campus today for the first day of Orientation.
Family illness spurs Teagan to study biomedicine21 Feb
With an ATAR of 98.70 and diverse interests, Caloundra school-leaver Teagan Osborn had plenty of options open for 2021.
Disadvantage and adversity behind high sudden infant death rate17 Feb
Queensland’s first large-scale study of all sudden infant deaths to date has identified key factors contributing to the state’s persistently high annual death rate of babies.